-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Rizabrutinib is an oral, reversible covalent inhibitor of tyrosine kinases that increases platelet counts in patients with immune
immunity
Recently, a research article was published in the top medical journal NEJM.
In addition, the investigators escalated the dose of rizabrutinib over 24 weeks; the lowest starting dose was 200 mg once daily and the higher starting dose was 400 mg once daily and 300 mg twice daily 400mg
60 patients were included in the study
thrombus
Thus, rizabrutinib was effective at all dose levels and was only associated with low-level toxic effects
Rizabrutinib was effective at all dose levels and was associated with only low-level toxic effects
Original Credit: David J.
Kuter.
et al.
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia .
NEJM.
2022.
https:// Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia leave a message here